Trials / Conditions / Meningococcal Vaccine

Meningococcal Vaccine

12 registered clinical trials studyying Meningococcal Vaccine.

Status	Trial	Sponsor	Phase
Completed	Trial to Describe the Safety, Tolerability, and Immunogenicity of Trumenba When Administered to Immunocompromi NCT04893811	Pfizer	Phase 4
Completed	Study to Evaluate the Safety and Immunogenicity of Nimenrix (Registered) in Healthy Infants, Given at 3 and 12 NCT04819113	Pfizer	Phase 3
Terminated	A Clinical Trial to Assess the Safety, Tolerability and Immunogenicity of MenABCWY in Healthy Infants NCT04645966	Pfizer	Phase 2
Completed	MenABCWY Noninferiority Study in Healthy Participants ≥10 to <26 Years of Age NCT04440163	Pfizer	Phase 3
Completed	A Trial to Describe the Safety and Immunogenicity of MenABCWY When Administered on 2 Schedules NCT04440176	Pfizer	Phase 2
Completed	Prospective Study on the Vaccine Response to Meningococcal B Vaccine After Allogeneic Stem Cell Transplantatio NCT03509051	Assistance Publique - Hôpitaux de Paris	N/A
Completed	Non Inferiority Trial of Locally Manufactured Meningococcal ACWY Vaccine 'Ingovax ACWY' in Bangladesh. NCT03263403	International Centre for Diarrhoeal Disease Research, Bangladesh	Phase 2 / Phase 3
Completed	A Trial to Describe the Immunogenicity and Safety of 2 Doses of Bivalent rLP2086 (Trumenba) and a Pentavalent NCT03135834	Pfizer	Phase 3
Completed	MenB Vaccine: Implementation Via Information, Empowerment and Accessibility NCT02975596	University of Florida	N/A
Completed	A Trial to Assess the Lot Consistency, Safety, Tolerability and Immunogenicity of Bivalent rLP2086 Vaccine Whe NCT01830855	Pfizer	Phase 3
Completed	A Trial to Assess the Safety, Tolerability and Immunogenicity of Repevax and rLP2086 Vaccine When Given Togeth NCT01323270	Pfizer	Phase 2
Completed	A Trial To Assess The Safety, Tolerability, And Immunogenicity Of Rlp2086 Vaccine When Administered In Either NCT01299480	Pfizer	Phase 2